Documents
Application Sponsors
| NDA 204767 | FRESENIUS KABI USA | |
Marketing Status
Application Products
| 001 | SOLUTION;INTRAVENOUS | 1GM/100ML (10MG/ML) | 0 | ACETAMINOPHEN | ACETAMINOPHEN |
FDA Submissions
| TYPE 5; Type 5 - New Formulation or New Manufacturer | ORIG | 1 | AP | 2015-10-28 | STANDARD |
| LABELING; Labeling | SUPPL | 3 | AP | 2020-11-13 | STANDARD |
| LABELING; Labeling | SUPPL | 7 | AP | 2021-06-23 | STANDARD |
| LABELING; Labeling | SUPPL | 8 | AP | 2021-07-28 | STANDARD |
Submissions Property Types
| ORIG | 1 | Null | 7 |
| SUPPL | 3 | Null | 6 |
| SUPPL | 7 | Null | 15 |
| SUPPL | 8 | Null | 15 |
CDER Filings
FRESENIUS KABI USA
cder:Array
(
[0] => Array
(
[ApplNo] => 204767
[companyName] => FRESENIUS KABI USA
[docInserts] => ["",""]
[products] => [{"drugName":"ACETAMINOPHEN","activeIngredients":"ACETAMINOPHEN","strength":"1GM\/100ML (10MG\/ML)","dosageForm":"SOLUTION;INTRAVENOUS","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"10\/28\/2015","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/204767s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"10\/28\/2015","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 5 - New Formulation or New Manufacturer","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/204767s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2015\\\/204767Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2015\\\/204767Orig1s000TOC.cfm\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2015-10-28
)
)